NYSE:NVTA

Invitae Stock Forecast, Price & News

$39.07
-0.31 (-0.79 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$38.94
Now: $39.07
$41.03
50-Day Range
$33.06
MA: $39.02
$43.72
52-Week Range
$13.34
Now: $39.07
$61.59
Volume3.36 million shs
Average Volume4.61 million shs
Market Capitalization$7.68 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.11
Invitae Corporation, a medical genetics company, integrates genetic information into healthcare decision-making by clinicians and patients in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Invitae logo

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone415-374-7782
Employees2,100
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$216.82 million
Book Value$3.93 per share

Profitability

Net Income$-241,960,000.00
Net Margins-183.50%

Miscellaneous

Market Cap$7.68 billion
Next Earnings Date5/4/2021 (Estimated)
OptionableOptionable

Headlines

Invitae (NYSE:NVTA) Receives "Buy" Rating from SVB Leerink
April 11, 2021 |  americanbankingnews.com
Is NVTA Stock A Buy or Sell? - Yahoo Finance
April 8, 2021 |  finance.yahoo.com
Invitae (NYSE:NVTA) Shares Up 4.5%
April 8, 2021 |  americanbankingnews.com
Is NVTA Stock A Buy or Sell?
April 7, 2021 |  finance.yahoo.com
InVitae (NVTA) to acquire Genosity - StreetInsider.com
April 5, 2021 |  streetinsider.com
Invitae (NYSE:NVTA) Shares Gap Up to $39.19
April 5, 2021 |  americanbankingnews.com
Invitae (NYSE:NVTA) Raised to Outperform at Oppenheimer
April 5, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.62 out of 5 stars

Medical Sector

374th out of 2,019 stocks

Medical Laboratories Industry

4th out of 39 stocks

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$39.07
-0.31 (-0.79 %)
(As of 04/14/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVTA News and Ratings via Email

Sign-up to receive the latest news and ratings for NVTA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Invitae (NYSE:NVTA) Frequently Asked Questions

Is Invitae a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Invitae stock.
View analyst ratings for Invitae
or view top-rated stocks.

What stocks does MarketBeat like better than Invitae?

Wall Street analysts have given Invitae a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Invitae wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Invitae's next earnings date?

Invitae is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Invitae
.

How were Invitae's earnings last quarter?

Invitae Co. (NYSE:NVTA) released its quarterly earnings results on Tuesday, February, 16th. The medical research company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.55) by $0.08. The medical research company had revenue of $100.43 million for the quarter, compared to analysts' expectations of $97.87 million. Invitae had a negative net margin of 183.50% and a negative trailing twelve-month return on equity of 81.19%.
View Invitae's earnings history
.

How has Invitae's stock been impacted by COVID-19?

Invitae's stock was trading at $15.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NVTA stock has increased by 146.5% and is now trading at $39.07.
View which stocks have been most impacted by COVID-19
.

What guidance has Invitae issued on next quarter's earnings?

Invitae updated its FY 2021 After-Hours earnings guidance on Wednesday, February, 17th. The company provided EPS guidance of for the period. The company issued revenue guidance of $450 million, compared to the consensus revenue estimate of $488.37 million.

What price target have analysts set for NVTA?

7 analysts have issued 12-month price objectives for Invitae's shares. Their forecasts range from $35.00 to $65.00. On average, they anticipate Invitae's share price to reach $49.33 in the next twelve months. This suggests a possible upside of 26.3% from the stock's current price.
View analysts' price targets for Invitae
or view top-rated stocks among Wall Street analysts.

Who are Invitae's key executives?

Invitae's management team includes the following people:
  • Dr. Sean Emerson George, Co-Founder, Pres, CEO & Chairman (Age 47, Pay $666.79k)
  • Ms. Shelly D. Guyer, Chief Financial Officer (Age 61, Pay $566.77k)
  • Dr. Robert L. Nussbaum, Chief Medical Officer (Age 71, Pay $500.09k)
  • Mr. Lee Bendekgey, Chief Policy Officer (Age 63, Pay $566.77k)
  • Ms. Katherine A. Stueland, Chief Commercial Officer (Age 45, Pay $545.13k)
  • Mr. Alex Furman, Co-Founder, Culture Tsar & Head of People Analytics
  • Ms. Michele Cargill Ph.D., Co-Founder, Key Projects & Advisor to the CEO
  • Mr. Kenneth D. Knight, Chief Operating Officer (Age 60)
  • Mr. Robert F. Werner, Chief Accounting Officer & Principal Accounting Officer (Age 48)
  • Mr. Layton Wedgeworth, Chief Technology Officer

What is Sean George's approval rating as Invitae's CEO?

59 employees have rated Invitae CEO Sean George on Glassdoor.com. Sean George has an approval rating of 87% among Invitae's employees.

Who are some of Invitae's key competitors?

What other stocks do shareholders of Invitae own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Square (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), The Trade Desk (TTD), Shopify (SHOP), salesforce.com (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

When did Invitae IPO?

(NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

What is Invitae's stock symbol?

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Who are Invitae's major shareholders?

Invitae's stock is owned by many different institutional and retail investors. Top institutional shareholders include Profit Investment Management LLC (0.07%), OTA Financial Group L.P. (0.03%), Phoenix Wealth Advisors (0.01%), Carnegie Capital Asset Management LLC (0.01%), AdvisorNet Financial Inc (0.00%) and Pacer Advisors Inc. (0.00%). Company insiders that own Invitae stock include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Randal W Scott, Robert F Werner, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida.
View institutional ownership trends for Invitae
.

Which major investors are selling Invitae stock?

NVTA stock was sold by a variety of institutional investors in the last quarter, including Profit Investment Management LLC, Phoenix Wealth Advisors, and Pacer Advisors Inc.. Company insiders that have sold Invitae company stock in the last year include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert L Nussbaum, Sean E George, Shelly D Guyer, and Thomas Brida.
View insider buying and selling activity for Invitae
or view top insider-selling stocks.

Which major investors are buying Invitae stock?

NVTA stock was purchased by a variety of institutional investors in the last quarter, including OTA Financial Group L.P., Carnegie Capital Asset Management LLC, AdvisorNet Financial Inc, Baldwin Brothers Inc. MA, and Westside Investment Management Inc..
View insider buying and selling activity for Invitae
or or view top insider-buying stocks.

How do I buy shares of Invitae?

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Invitae's stock price today?

One share of NVTA stock can currently be purchased for approximately $39.07.

How much money does Invitae make?

Invitae has a market capitalization of $7.68 billion and generates $216.82 million in revenue each year. The medical research company earns $-241,960,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis.

How many employees does Invitae have?

Invitae employs 2,100 workers across the globe.

What is Invitae's official website?

The official website for Invitae is www.invitae.com.

Where are Invitae's headquarters?

Invitae is headquartered at 1400 16th Street, SAN FRANCISCO CA, 94103.

How can I contact Invitae?

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]


This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.